We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Identify the Next Optimal Clinical Candidate - Faster

PerkinElmer has launched Lead Discovery Premium, which builds on decades of experience with chemical Structure-Activity Relationship (SAR) tools and biological Sequence-Activity Relationship (bio-SAR), delivering unified, interactive, responsive, data agnostic access to all users.

This white paper outlines how an integrated platform can provide powerful and incisive chemical and biological analytics required to identify the next optimal clinical candidate.

Download this white paper to discover how:

  • A unified platform enables researchers to gain a deeper understanding of the structure and properties of potential new biologic and small molecule therapeutics
  • PerkinElmer’s Lead Discovery Premium combines and delivers advanced biological sequence and chemical structural intelligence tools
  • The user-friendly analysis and visualization environment will facilitate rapid data organization, exploration and decision making